

# Curriculum vitae

Dr. Paul Peter Manka, Universitätsklinikum Knappschaftskrankenhaus Bochum,  
Medizinische Klinik, In der Schornau 23-35, 44892 Essen, paul.manka@kk-bochum.de

## **Personal Information:**

Name: Paul Peter Manka  
Nationality: German  
Academic degree: M.D. (Dr. med.)

## **Professional Experience:**

Since 01/2021 Resident (Facharzt)  
Department of Medicine  
Prof A. Canbay  
University Hospital Bochum  
Knappschaftskrankenhaus, Germany

05/2020 – 12/2020 Resident (Facharzt, Funktionsoberarzt)  
Gastroenterology and Hepatology  
Prof H. Wedemeyer  
Prof C. Lange  
University Hospital Essen, Germany

04/2017 – 04/2020 Resident (Assistenzarzt)  
Gastroenterology and Hepatology  
Prof H. Wedemeyer  
Prof C. Lange  
University Hospital Essen, Germany

06/2016 – 03/2017 Clinical Research Fellow  
Medical University South Carolina (MUSC)  
Gastroenterology and Hepatology  
Department of Medicine  
Prof Wing-Kin Syn, MD  
Prof Don Rockey, MD  
Charleston (SC), United States of America

11/2015 – 03/2017 Honorary Lecturer  
King's College London  
Faculty of Life Science and Medicine  
Division of Transplantation, Immunology and  
Mucosal Biology  
Prof A. Sanchez-Fueyo  
London, United Kingdom

04/2014 – 03/2017 Clinical Research Fellow  
Institute of Hepatology, London, UK  
Prof R. Williams  
Liver Regeneration and Repair Group  
Dr WK Syn  
London, United Kingdom

09/2011 – 03/2014 Resident (Assistenzarzt)

Gastroenterology and Hepatology  
Prof G. Gerken  
University Hospital Essen, Germany

2007-2011  
Student assistant, transplant coordination  
Department of Surgery  
Prof A. Paul  
University Hospital Essen, Germany

**Doctoral Thesis:**

2011  
‘The role of serum based modifications of the MELD and the influence of adiponectin in predicting outcome in acute liver failure’ *Magna cum laude*

**Licensure:**

12/2010  
Medical License (Approbation)  
05/2020  
Specialization in Internal Medicine and  
Gastroenterology (Facharzt)

**Clinical Electives:**

03/2010- 07/2010  
Prof. Dr. med. M. Forsting, M.D., Institute of  
Radiology, University Hospital Essen, Germany  
02/2010- 03/2010  
Prof. Dr. med. D. Nast- Kolb, M.D., Department of  
Traumatology, University Hospital Essen, Germany  
12/2009 - 02/2010  
Prof. Dr. med. A. Paul, M.D., Department of  
Surgery, University Hospital Essen, Germany  
08/2009 - 10/2009  
Prof. R.H. Holloway, M.D., Department of  
Gastroenterology, Hepatology and General Medicine  
Royal Adelaide Hospital, University of Adelaide,  
Australia  
03/2009  
Univ.-Doz. Dr. A. Podczeck-Schweighofer, M.D.,  
5th Medical Department, Kaiser Franz Josef  
Hospital, Vienna, Austria  
02/2007 – 09/2007  
Univ. Prof. Dr. C. Leithner, M.D.,  
1st Medical Department, Kaiser Franz Josef  
Hospital, Vienna, Austria

**Academics:**

2010  
Second part of the medical examination/ medical  
license  
2006  
First part of the medical examination

**Scientific Training:**

09/2014  
NIHR Infrastructure/ BASL Training Workshop 2014  
- Fibrosis, Hilton Newcastle Gateshead 14 September

2014 (UK)

12/2013

EASL Clinical School of Hepatology Course 21:  
“General Hepatology”  
de Gottardi, Dufour, Bern (Switzerland)

### **Extra Curricular Courses and Activities:**

2013	Theoretical lectures in handling experimental animals, Prof. Hillen, Department of Veterinary Medicine University Hospital Essen, Germany
2012	GCP Certificate
09/2017	GCP-Refresher
11/2020	GCP-Grundlagen- und Aufbaukurs

### **Clinical Studies participation**

#### **Alexion ALX-LALD-501 EudraCT Number: 2019-0002430-3634**

An observational disease and clinical outcomes registry of patients with Lysosomal Acid Lipase (LAL) deficiency

**11/2020 – 12/2020, Role: Subinvestigator**

#### **BI 1386-004**

**EudraCT Number: 2016-000499-83**

A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and pharmacokinetics of different doses of orally administered BI 1467335 during a 12-week treatment period compared to placebo in patients with clinical evidence of NASH.

**02/2018 – 03/2019, Role: Subinvestigator**

#### **REGENERATE**

**EudraCT Number: 2015-002560-16**

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis

**01/2017 – 04/2018, Role: Subinvestigator**

#### **GFT505-315-1**

**EudraCt Number: 2015-005385-38**

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis

**07/2017 – 04/2018, Role: Subinvestigator**

### **Membership in scientific organisations:**

Since 06/2016	American Association for the Study of Liver Diseases (AASLD)
Since 09/2014	British Association for the Study of Liver (BASL annual meeting BASL)
Since 01/2014	“German Association for Internal Medicine”(DGIM)
Since 03/2013	“German Association for Digestive and Metabolic Disorders” (DGVS)

Since 03/2013

European Association for the Study of the Liver  
(EASL)

### **Grants and Awards:**

04/2015	EASL Sheila Sherlock Entry-Level Research Fellowship
04/2015	DFG (German Research Foundation) Research Fellowship
09/2014	Norgine BASL Bursary
09/2014	BASL Travel Grant (BASL annual meeting)
12/2013	EASL Travel Grant (EASL school)
06/2013	German Liver Foundation Short-term Fellowship

### **Publications**

#### ***Peer review manuscripts***

- Sydor S, **Manka P**, *et al.* Hepatocyte KLF6 Expression Affects FXR Signalling and the Clinical Course of Primary Sclerosing Cholangitis. *Liver Int. Off. J. Int. Assoc. Study Liver.* 2020.
- Sydor S, Best J, Messerschmidt I, **Manka P**, *et al.* Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC. *Clin. Transl. Gastroenterol.* 2020.
- Hoyer DP, Benkö T, **Manka P**, *et al.* Long-term Outcomes After Controlled Oxygenated Rewarming of Human Livers Before Transplantation. *Transplant. Direct.* 2020.
- Schotten C, Bechmann LP, **Manka P** *et al.* NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization. *Liver Cancer.* 2019.
- **Manka P**, Bechmann LP, *et al.* Low Free Triiodothyronine Is Associated With Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis. *Dig. Dis. Sci.* 2019.
- Gottlieb A, Kottmann M, **Manka P**, *et al.* How to Define Acute Liver Failure Patients With Pre-Existing Liver Disease Without Signs of Cirrhosis. *Dig. Dis. Basel Switz.* 2019.
- Shetty A, Hsu JW, **Manka P**, Syn WK. Role of the Circadian Clock in the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. *Dig. Dis. Sci.* 2018. doi:10.1007/s10620-018-5242-x
- Buechter M, **Manka P**, *et al.* Potential Triggering Factors of Acute Liver Failure as a First Manifestation of Autoimmune Hepatitis-A Single Center Experience of 52 Adult Patients. *World J. Gastroenterol.* 2018.
- **Manka P**, Coombes JD, Boosman R, *et al.* Thyroid hormone in the regulation of hepatocellular carcinoma and its microenvironment. *Cancer Lett* 2018;419:175–86.
- Metha K, Coombes JD, Briones-Orta M, **Manka P**, *et al.* Iron Enhances Hepatic Fibrogenesis and Activates Transforming Growth Factor- $\beta$  Signaling in Murine Hepatic Stellate Cells. *Am. J. Med. Sci.* 2018.
- Thodou V, Buechter M, **Manka P**, *et al.* Course of hepatitis E infection in a patient with rheumatoid arthritis and autoimmune hepatitis: A case report. *Medicine (Baltimore)* 2017;96:e9407.
- Buechter M, **Manka P**, Gerken G, *et al.* Transjugular Intrahepatic Portosystemic Shunt in Patients with Portal Hypertension: Patency Depends on Coverage and Interventionalist's Experience. *Dig Dis Basel Switz* 2018;36:218–27.

- Buechter M, **Manka P**, Theysohn JM, *et al.* Spleen stiffness is positively correlated with HVPG and decreases significantly after TIPS implantation. *Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver* 2018;50:54–60.
- Sydor S, **Manka P**, *et al.* Krüppel-like Factor 6 Is a Transcriptional Activator of Autophagy in Acute Liver Injury. *Sci. Rep.* 2017.
- Buechter M, Kahraman A, **Manka P**, *et al.* Partial spleen embolization reduces the risk of portal hypertension-induced upper gastrointestinal bleeding in patients not eligible for TIPS implantation. *PLoS One* 2017;12:e0177401.
- Buechter M, **Manka P**, Heinemann FM, *et al.* Outcome and Genetic Factors in IgG4-Associated Autoimmune Pancreatitis and Cholangitis: A Single Center Experience. *Gastroenterol Res Pract* 2017;2017:6126707.
- Anastasiou OE, Kälsch J, Hakmouni M, **Manka P**, *et al.* Low transferrin and high ferritin concentrations are associated with worse outcome in acute liver failure. *Liver Int Off J Int Assoc Study Liver* 2017;37:1032–41.
- Best, J., Bilgi, H., Heider, D., Schotten, C., **Manka, P.**, Bedreli, S., Gorray, M., Ertle, J., van Grunsven, L.A., and Dechêne, A. (2016). The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. *Z Gastroenterol* 54, 1296–1305.
- Buechter, M., Theysohn, J.M., Kahraman, A., **Manka, P.**, Gerken, G., Canbay, A., and Dechêne, A. (2016a). Rescue therapy of a refractory rectal variceal bleeding in a cirrhotic patient by Linton-Nachlas tube and TIPS implantation in combination with variceal embolization. *Z Gastroenterol*.
- Buechter, M., Kahraman, A., **Manka, P.**, Gerken, G., Jochum, C., Canbay, A., and Dechêne, A. (2016b). Spleen and Liver Stiffness Is Positively Correlated with the Risk of Esophageal Variceal Bleeding. *Digestion* 94, 138–144.
- **Manka, P.**, Verheyen, J., Gerken, G., and Canbay, A. (2016). Liver Failure due to Acute Viral Hepatitis (A-E). *Visc Med* 32, 80–85.
- Coombes JD, Choi SS, Swiderska-Syn M, **Manka P**, Reid DT, Palma E, *et al.* Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis. *Biochim. Biophys. Acta.* 2016
- Kälsch J, Bechmann LP, Heider D, Best J, **Manka P**, Kälsch H, *et al.* Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort. *Sci Rep* 2015
- Kathemann S, Bechmann LP, Sowa J-P, **Manka P**, Dechêne A, Gerner P, *et al.* Etiology, outcome and prognostic factors of childhood acute liver failure in a German Single Center. *Ann Hepatol* 2015
- Anastasiou O, Sydor S, Sowa J-P, **Manka P**, Katsounas A, Syn W-K, *et al.* Higher Thyroid-Stimulating Hormone, Triiodothyronine and Thyroxine Values Are Associated with Better Outcome in Acute Liver Failure. *PLoS ONE* 2015
- Juntermanns B, **Manka P**, Hoyer DP, Kaiser GM, Radunz S, Pracht W, *et al.* Infectious complications in the era of MELD. *Ann Transplant* 2015;20:297–302.
- Best J, **Manka P**, Syn W-K, Dollé L, van Grunsven LA, Canbay A (2015). Role of liver progenitors in liver regeneration. *Hepatobiliary Surg Nutr* 2015; 4:48-58
- **Manka P**, Bechmann LP, Coombes JD, Thodou V, Schlattjan M, Kahraman A, *et al.* Hepatitis E Virus Infection as a Possible Cause of Acute Liver Failure in Europe. *Clin Gastroenterol Hepatol* 2015.

- Bechmann LP, **Manka P**, Best J, Saner FH, Paul A, et al. (2014) Drug-induced liver injury as predominant cause of acute liver failure in a monocenter study. *Dtsch Med Wochenschr* 139: 878–882.
- **Manka P**, Olliges V, Bechmann LP, Schlattjan M, Jochum C, et al. (2014) Low levels of blood lipids are associated with etiology and lethal outcome in acute liver failure. *PLoS ONE* 9: e102351.
- **Manka P**, Bechmann LP, Tacke F, Sowa J-P, Schlattjan M, et al. (2013) Serum sodium based modification of the MELD does not improve prediction of outcome in acute liver failure. *BMC Gastroenterol* 13: 58.
- Best J, Dollé L, **Manka P**, Coombes J, van Grunsven LA, et al. (2013) Role of liver progenitors in acute liver injury. *Front Physiol* 4: 258.
- Kälsch J, Bechmann LP, **Manka P**, Kahraman A, Schlattjan M, et al. (2013) Non-alcoholic steatohepatitis occurs in celiac disease and is associated with cellular stress. *Z Gastroenterol* 51: 26–31.
- Jochum C, Gieseler RK, Gawlista I, Fiedler A, **Manka P**, et al. (2009) Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. *Digestion* 80: 235–240.

Bochum, April 14th 2021,



Paul Manka